TY  - JOUR
AU  - Casabonne, Delphine
AU  - Benavente, Yolanda
AU  - Seifert, Julia
AU  - Costas, Laura
AU  - Armesto, Maria
AU  - Arestin, Maria
AU  - Besson, Caroline
AU  - Hosnijeh, Fatemeh S
AU  - Duell, Eric J
AU  - Weiderpass, Elisabete
AU  - Masala, Giovanna
AU  - Kaaks, Rudolf
AU  - Canzian, Federico
AU  - Chirlaque, Maria-Dolores
AU  - Perduca, Vittorio
AU  - Mancini, Francesca R
AU  - Pala, Valeria
AU  - Trichopoulou, Antonia
AU  - Karakatsani, Anna
AU  - La Vecchia, Carlo
AU  - Sanchez-Perez, Maria-Jose
AU  - Tumino, Rosario
AU  - Gunter, Marc J
AU  - Amiano, Pilar
AU  - Panico, Salvatore
AU  - Sacerdote, Carlotta
AU  - Schmidt, Julie A
AU  - Boeing, Heiner
AU  - Schulze, Matthias B
AU  - Barricarte, Aurelio
AU  - Riboli, Elio
AU  - Olsen, Anja
AU  - Tjønneland, Anne
AU  - Vermeulen, Roel
AU  - Nieters, Alexandra
AU  - Lawrie, Charles H
AU  - de Sanjose, Silvia
PY  - 2019
DO  - 10.1002/ijc.32894
UR  - http://hdl.handle.net/10668/15036
T2  - International journal of cancer
AB  - Chronic lymphocytic leukemia (CLL) is an incurable disease accounting for almost one-third of leukemias in the Western world. Aberrant expression of microRNAs (miRNAs) is a well-established characteristic of CLL, and the robust nature of miRNAs makes...
LA  - en
PB  - John Wiley & Sons, Inc.
KW  - chronic lymphocytic leukemia
KW  - circulating miRNA
KW  - prospective study
KW  - serum
KW  - Biomarkers, Tumor
KW  - Case-Control Studies
KW  - Europe
KW  - Female
KW  - Humans
KW  - Leukemia, Lymphocytic, Chronic, B-Cell
KW  - Male
KW  - MicroRNAs
KW  - Middle Aged
KW  - Odds Ratio
KW  - Predictive Value of Tests
KW  - Prospective Studies
KW  - Up-Regulation
TI  - Serum levels of hsa-miR-16-5p, hsa-miR-29a-3p, hsa-miR-150-5p, hsa-miR-155-5p and hsa-miR-223-3p and subsequent risk of chronic lymphocytic leukemia in the EPIC study.
TY  - research article
VL  - 147
ER  -